Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pet Pharm Biotech CoROCO:7762 +0.20%19 Net Margin % is 12.25% as of Dec. 2025, which is 30% above its 10-year median of 9.43. GuruFocus rates ROCO:7762 with a GF Score™ of 19/100. The stock has 5 warning signs investors should review. Among 960 Drug Manufacturers companies, Pet Pharm Biotech Co ranks better than 67.5% on this metric.
The historical rank and industry rank for Pet Pharm Biotech Co's Net Margin % or its related term are showing as below:
ROCO:7762'
s Net Margin % Range Over the Past 10 Years
Min: -5.03 Med: 9.43 Max: 11.25
Current: 11.25
ROCO:7762's Net Margin % is ranked better than 67.5% of 960
companies
in the Drug Manufacturers industry
Industry Median: 5.635
vs ROCO:7762: 11.25
Pet Pharm Biotech Co (ROCO:7762) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Pet Pharm Biotech Co Net Margin % Related Terms
Pet Pharm Biotech Co Net Margin % Historical Data
* Premium members only.
The historical data trend for Pet Pharm Biotech Co's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7762 vs LLY, JNJ, ABBV: Net Margin % Comparison
For the Drug Manufacturers - General subindustry, Pet Pharm Biotech Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pet Pharm Biotech Co Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pet Pharm Biotech Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where Pet Pharm Biotech Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pet Pharm Biotech Co (ROCO:7762) has a Net Margin % of 12.25% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Pet Pharm Biotech Co and its competitors. This is 30% above median its historical median of 9.43. According to the industry distribution chart, Pet Pharm Biotech Co ranks #312 out of 960 companies in the Drug Manufacturers industry, placing it in the top 32.5%.
Is Pet Pharm Biotech Co's Net Margin % too high?
Pet Pharm Biotech Co's current Net Margin % of 12.25% is 30% above median its 10-year median of 9.43. The Drug Manufacturers industry median Net Margin % is 5.64. Pet Pharm Biotech Co's value of 12.25% is 117.4% above this industry median. Based on the distribution chart, Pet Pharm Biotech Co ranks #312 out of 960 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Pet Pharm Biotech Co has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Pet Pharm Biotech Co's Net Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Pet Pharm Biotech Co ranks #312 out of 960 companies for Net Margin %. This puts Pet Pharm Biotech Co in the upper half of its industry. The industry median Net Margin % is 5.64. Pet Pharm Biotech Co's value of 12.25% is 117.4% above this benchmark. While the company's 10-year median is 9.43 vs. the industry median of 5.64, Pet Pharm Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.64, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pet Pharm Biotech Co's current Net Margin % of 12.25% is 117.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Pet Pharm Biotech Co and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pet Pharm Biotech Co's current Net Margin % is 12.25%, which is 30% above median its own 10-year median of 9.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pet Pharm Biotech Co stock overvalued right now?
Pet Pharm Biotech Co (ROCO:7762) has a current Net Margin % of 12.25%. The current Net Margin % is 12.25%, which is 30% above median its 10-year median of 9.43 and 117.4% above the Drug Manufacturers industry median of 5.64. Pet Pharm Biotech Co's overall GF Score™ is 19/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Pet Pharm Biotech Co (ROCO:7762), the current Net Margin % is 12.25% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pet Pharm Biotech Co Ltd is a Pharmaceutical company. The company is engaged in manufacturing medicinal products and medicine drugs. The products offered by the company include FDG Fluodeoxyglucose Injection (18F-FDG), Naolixi Injection (18F-FBB), Sodium fluoride injection (18F-NaF), and others.
19GF Score
Get the complete analysis for ROCO:7762
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7762 has been successfully added to your 
